Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Furthermore, Indivior’s extended-release buprenorphine, SUBLOCADE, has shown efficacy in reducing opioid use in patients with opioid use disorder, as demonstrated in a recent clinical trial. The trial ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

Milestones Include Top-Tier 3-Year Accreditations from OASAS and The Joint Commission, Staff Growth to Over 20 ...

Sublocade worldwide net revenue is expected to reach $905-$945 million, compared to analyst consensus of $898.9 million. InvestingPro analysis indicates Indivior has a PEG ratio of just 0.15, ...